Related Experiment Video

Updated: Aug 9, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Nivolumab and relatlimab for the treatment of melanoma

Xuan-Yu Chen1,2, Yi-Dong Li2, Yuhao Xie1,2

  • 1Institute for Biotechnology, St. John's University, Queens, New York City, New York, USA.

Drugs of Today (Barcelona, Spain : 1998)
|February 22, 2023
PubMed

Insights

Nivolumab and relatlimab combination therapy offers a significant improvement in progression-free survival for melanoma patients. This immunotherapy approach shows promise for treating advanced melanoma, overcoming limitations of prior treatments.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Melanoma is a deadly skin cancer with limited treatment options for metastatic stages.
  • Early diagnosis and surgery improve survival for nonmetastatic melanoma.
  • Immunotherapy resistance and toxicity pose challenges in melanoma treatment.

Approach:

  • Review of melanoma pathogenesis and the pharmacology of nivolumab and relatlimab.
  • Summary of anti-lymphocyte activation protein 3 (LAG-3) and anti-programmed cell death protein 1 (PD-1) drugs in cancer.
  • Discussion on the combination of nivolumab and relatlimab for melanoma treatment.

Key Points:

  • Nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) are novel immunotherapy agents.
  • The combination of nivolumab and relatlimab was FDA-approved in 2022 for melanoma.
  • Clinical trials show over a 2-fold increase in progression-free survival (PFS) with the combination compared to nivolumab alone.

Conclusions:

  • The nivolumab-relatlimab combination represents a significant advancement in metastatic melanoma treatment.
  • This dual immunotherapy may overcome resistance mechanisms and improve patient outcomes.
  • Further research and clinical application of PD-1 and LAG-3 inhibitors are warranted.
Keywords:
Cancer immunotherapyImmune checkpoint inhibitorsMelanomaNivolumabPD-1/PD-L1, LAG-3Relatlimab

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
612
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
469
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K